Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Clinical Trial to Evaluate the Effectiveness of Liver Shear Wave Quantization Detector Spleen Stiffness Value in the Diagnosis of Esophageal Varices

4 augustus 2026 bijgewerkt door: Hong You, Beijing Friendship Hospital

Esophageal variceal bleeding is one of the serious and life-threatening complications of chronic liver disease (CLD). Studies have shown that the prevalence of esophageal varices (EV) in patients with liver cirrhosis is about 50%-60%. The annual incidence of variceal bleeding in these patients is about 5%-15%, and the rebleeding rate can reach 30%-40% within 6 weeks after the first bleeding. The 6-week mortality related to variceal bleeding is as high as 10%-20%, which seriously threatens the life safety of patients with liver disease. Clinically, esophagogastroduodenoscopy (EGD) is the gold standard for the diagnosis and grading of esophageal varices. However, EGD is an invasive examination, which has certain application limitations such as related complications and high cost, which limits the promotion and application of this technology.

Therefore, there is an urgent need for an accurate, convenient and non-invasive method for esophageal varices. To address this clinical pain point, Baveno VII guidelines state that spleen stiffness measurement (SSM) based on vibration-controlled transient elastography (TE) can be used as a noninvasive marker to predict esophageal varices (EV). Several studies have shown that SSM measured by TE has good diagnostic performance in relation to the occurrence and severity of esophageal varices. A study involving 191 patients with liver disease showed that spleen stiffness was significantly higher in patients with varices than in those without varices (63.69 vs 47.78 kPa, P<0.0001), and the AUC of SSM for the diagnosis of EV was 0.74. In another study involving 260 patients with chronic liver disease, the AUC of SSM was 0.728 (95% CI: 0.665-0.791) for EV and 0.780 (95% CI: 0.714-0.846) for high-risk varix (HRV). The above results indicate that SSM has good clinical value in the prediction of EV.

Pro9000X, a liver function shear wave quantization detector based on vibration control TE, has been developed by Wuxi Hisiel Medical Technology Co., LTD. The device integrates ultrasound image positioning and TE function, aiming to achieve rapid, quantitative and non-invasive detection of liver stiffness measurement (LSM) and SSM. The results of EGD examination were used as the gold standard to evaluate the diagnostic performance of the spleen stiffness value detected by Pro9000X in patients with chronic liver disease, and the main evaluation indicators were the sensitivity and specificity of EV diagnosis. Secondary evaluation included AUROC, optimal cut-off value and diagnostic value of high-risk EV.

Studie Overzicht

Studietype

Observationeel

Inschrijving (Geschat)

246

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

NVT

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Patients with chronic liver disease who met the protocol inclusion and exclusion criteria

Beschrijving

Inclusion Criteria:

  1. Age over 18 years old, male or female;
  2. patients with clinically diagnosed chronic liver disease, including hepatitis C virus (HCV) infection, hepatitis B virus (HBV) infection, fatty liver disease, autoimmune liver disease, and alcoholic liver disease *;
  3. Liver stiffness measurement (LSM) ≥10kPa during screening or within one month before screening [4];
  4. able to communicate well with the investigators, understand and comply with the requirements of the study;
  5. Informed consent was signed voluntarily.

Exclusion Criteria:

  1. alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥250 U/L;
  2. complicated with jaundice (serum total bilirubin ≥50 μmol/L);
  3. complicated with important organ diseases (except liver) or serious systemic diseases (such as malignant tumors and HIV);
  4. after liver transplantation or TIPS;
  5. after splenectomy, splenic embolization or other portasystemic shunts;
  6. patients with moderate-to-large amount of ascites;
  7. unstable condition in the acute stage of esophageal variceal bleeding;
  8. combined with liver malignant tumors;
  9. patients with non-cirrhotic portal hypertension, Budd-Chiari syndrome and other hepatic vascular diseases; Acute or chronic portal vein thrombosis;
  10. unhealed wounds or scars in the left abdomen were not suitable for ultrasound examination;
  11. pregnant women;
  12. Other conditions judged by the investigators as not suitable for participating in the study.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Tijdsspanne
The results of esophagogastric duodenoscopy (EGD) were used as the gold standard to evaluate the diagnostic performance of spleen stiffness value detected by liver function shear wave quantization detector Pro9000X for esophageal varices (EV) in patients
Tijdsspanne: day 1: Screening period visit(Sign the informed consent form, meet the inclusion and exclusion criteria, et al) day 2-day 30: Trial visit during the period of experimentation (EGD and Pro9000X Spleen Hardness Examination) day 31: Pre-group visitation
day 1: Screening period visit(Sign the informed consent form, meet the inclusion and exclusion criteria, et al) day 2-day 30: Trial visit during the period of experimentation (EGD and Pro9000X Spleen Hardness Examination) day 31: Pre-group visitation

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

20 augustus 2026

Primaire voltooiing (Geschat)

30 oktober 2026

Studie voltooiing (Geschat)

30 oktober 2026

Studieregistratiedata

Eerst ingediend

24 juli 2026

Eerst ingediend dat voldeed aan de QC-criteria

4 augustus 2026

Eerst geplaatst (Werkelijk)

7 augustus 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

7 augustus 2026

Laatste update ingediend die voldeed aan QC-criteria

4 augustus 2026

Laatst geverifieerd

1 augustus 2026

Meer informatie

Termen gerelateerd aan deze studie

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren